Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2012-09-06 17:15:17
Reporting Period:
Filing Date:
Accepted Time:
2012-09-06 17:15:17
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1097264 Allos Therapeutics Inc ALTH Pharmaceutical Preparations (2834) 541655029
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
831547 Spectrum Pharmaceuticals Inc 11500 South Eastern Avenue, Suite 240
Henderson NV 89052
No No Yes No
1557619 Sapphire Acquisition Sub, Inc. C/o Spectrum Pharmaceuticals, Inc.
11500 South Eastern Avenue, Suite 240
Henderson NV 89052
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-09-05 130,854,840 $1.82 1,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
  1. Reflects all outstanding shares of Allos Therapeutics, Inc. ("Allos") not acquired in the tender offer described in the Tender Offer Statement on Schedule TO, as amended and supplemented, initially filed with the Securities and Exchange Commission on April 16, 2012 (the "Tender Offer") by Spectrum Pharmaceuticals, Inc. ("Spectrum") and Sapphire Acquisition Sub, Inc. ("Merger Sub"). On September 5, 2012, following completion of the Tender Offer, Allos merged with Merger Sub, with Allos surviving the merger as a wholly owned subsidiary of Spectrum pursuant to a "short-form merger" under Delaware law (the "Merger"). Outstanding shares of Allos not tendered in the Tender Offer are deemed acquired by Spectrum and Merger Sub upon consummation of the Merger.
  2. Prior to the Merger, Spectrum held 1,000 shares of the common stock of Merger Sub, which represented all of the issued and outstanding capital stock of Merger Sub. At the effective time of the Merger, each share of Merger Sub was converted into a share of Allos stock. At the effective time of the Merger, all shares of Allos issued and outstanding immediately prior to the effective time were cancelled as a result of the Merger, in effect cancelling all shares of Allos held by Merger Sub.